Aventis Pharmaceuticals Inc.

Edward Orton

Joseph M Salvino

Beverly C Langevin

John E Airey

Daniel Sherer

Paul H Krolikowski

Vasant K Nagulapalli

The present invention is directed to dihydrogen phosphate salt 2-(3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid of Formula (III), a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of Formula (III), and a pharmaceutically acceptable carrier; and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like, by administering to said patient a pharmaceutically effective amount of the compound of Formula (III).

Dihydrogen phosphate salt of a prostaglandin D2 receptor antagonist

This invention is directed to the use of F NMR spectroscopy to monitor and quantitate solid-phase reactions and fluorine-containing solid-phase reagents useful therefor.

Method and reagents for the quantification of solid-phase reactions using fluorine NMR

Growing community of inventors

Berkley Heights, NJ, United States of America

Edward Orton